Mode
Text Size
Log in / Sign up

Cortical Superficial Siderosis Burden Predicts Hemorrhage and Poor Outcomes After Stroke ThrombolysisNew Brain Scan Marker Predicts Bleeding Risk Before Treatment

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider cortical superficial siderosis burden on MRI when weighing hemorrhagic risk versus benefit of stroke thrombolysis.

This MRI substudy of the AcT trial (Alteplase Compared to Tenecteplase) examined whether radiological Boston cerebral amyloid angiopathy (CAA) criteria and their constituent imaging markers predict hemorrhagic and functional outcomes after intravenous thrombolysis for acute ischemic stroke. Blinded raters scored lobar cerebral microbleeds, cortical superficial siderosis, white matter hyperintensity multispot sign, and centrum semiovale enlarged perivascular spaces, and classified possible and probable CAA using Boston criteria versions 1.0, 1.5, and 2.0.

Of 1600 AcT trial patients, 482 had suitable MRI (mean age 71 years; 47.1% female). Multivariable regression adjusted for age, sex, baseline stroke severity, diabetes, hypertension, onset-to-needle time, thrombolytic agent, and endovascular therapy. Cortical superficial siderosis emerged as the dominant harmful marker: each additional affected sulcus was associated with symptomatic ICH (aOR 3.88 [95% CI, 2.87-5.26]), any ICH (aOR 1.91 [95% CI, 1.22-2.98]), 90-day mortality (aOR 1.42 [95% CI, 1.18-1.71]), worse modified Rankin Scale scores (adjusted common OR 1.74 [95% CI, 1.58-1.91]), and lower odds of excellent recovery (mRS 0-1; aOR 0.70 [95% CI, 0.64-0.77]).

Probable Boston criteria versions 1.0 and 1.5 were associated with increased odds of any ICH (aOR 2.57 and 2.39, respectively); possible criteria version 1.5 with worse mRS (adjusted common OR 2.34 [95% CI, 1.30-4.22]). Boston criteria version 2.0 were not significantly associated with any hemorrhagic outcome.

Limitations: this is an observational substudy of a subset with suitable MRI, so associations are not causal; adverse-event rates beyond the prespecified hemorrhage and outcome end points were not reported here. Findings should be weighed alongside overall clinical benefit of thrombolysis rather than used alone to withhold treatment.

A specific brain scan pattern predicts dangerous bleeding after clot-busting drugs.

Who it helps

Patients with stroke who need fast treatment to save their brains.

The Catch

This tool helps doctors decide, but the treatment itself is not new.

One powerful sentence

This new scan detail helps doctors see who is at highest risk before giving life-saving medicine.

Imagine you are waiting in an emergency room. A loved one has had a stroke. Their brain is blocked. Time is running out. Doctors must decide quickly: do we give medicine to dissolve the clot? Or is the risk of bleeding too high?

This decision is hard. It feels like walking a tightrope.

Strokes are common. They happen to millions of people every year. Many of these strokes are caused by a blockage in a brain artery. This is called an ischemic stroke.

Doctors often give a drug called tissue plasminogen activator, or tPA. This drug acts like a key to unlock the blockage. It can save brain tissue and improve recovery.

But there is a danger. The same drug that opens the blockage can also cause bleeding inside the brain. This is called a hemorrhage. It can be life-threatening.

Doctors look at many things to decide on treatment. They check blood pressure. They check how long it has been since symptoms started. They also look at brain scans.

However, there is a specific condition called cerebral amyloid angiopathy, or CAA. This is a buildup of protein in the blood vessels of the brain. It makes the vessels weak and leaky.

For a long time, doctors were unsure how to spot CAA on standard scans. They worried that if they missed it, they might give a dangerous dose of medicine.

The surprising shift

For years, researchers looked at different signs on MRI scans. They checked for tiny spots of bleeding. They looked at white matter changes.

But none of these signs were perfect. Some patients had signs but bled anyway. Others had no signs but still had trouble.

Then, a new study changed the picture. Researchers looked at over 1,600 patients in a major trial. They used a specific set of rules called the Boston Criteria to read the scans.

What scientists didn't expect

The team found one specific sign stood out from the rest. It was called cortical superficial siderosis.

Think of your brain like a busy city. The blood vessels are the roads. In CAA, the roads get rusty and worn out.

Cortical superficial siderosis looks like rust on the surface roads of the brain. It shows up as dark lines on the MRI scan.

The researchers found that the amount of this "rust" was the most important clue. Every extra line of rust on the scan meant a much higher risk of bleeding.

The risk was huge. For every additional line seen on the scan, the chance of bleeding jumped significantly. It also made death and long-term disability more likely.

The twist in the story

Here is where things get interesting. The study looked at different versions of the Boston Criteria. These are like checklists doctors use to read scans.

When patients met the older checklists, the risk of bleeding went up. But when they used the newest checklist, the risk did not seem to change the outcome.

This suggests the newest rules might be better at spotting true danger. The older rules might have flagged some patients who were actually safe.

This news is important for patients and families. It gives doctors a sharper tool. They can now see the "rust" on the brain's surface.

If this rust is heavy, the doctor knows the bleeding risk is high. They can talk to the family about the risks and benefits. They might choose a different treatment plan.

This does not mean this treatment is available yet. The medicine itself is standard. But the way doctors read the scan is getting better.

You should talk to your doctor if you have questions. Ask them if they use the latest scan rules. Ask if they look for this specific sign.

The catch

There is a limit to what this study tells us. The study looked at patients who already had a stroke. It did not test people who had never had a stroke.

Also, the study was done in one large group of patients. We need more studies to see if this works everywhere.

What happens next? Doctors will use this new information in their daily work. They will weigh the risk of bleeding against the chance of saving brain tissue.

Researchers will continue to study these scan markers. They want to make sure every patient gets the safest possible care.

This research helps turn complex science into a simple decision. It protects patients while still giving them a chance to recover.

Study Details

Study typeRct
Sample sizen = 1,600
EvidenceLevel 2
Follow-up852.0 mo
PublishedApr 2026
View Original Abstract ↓
BACKGROUND: Cerebral amyloid angiopathy (CAA) is thought to increase the risk of postthrombolytic intracranial bleeding, yet CAA neuroimaging markers and magnetic resonance imaging criteria have not been systematically evaluated in large acute stroke trials. We, therefore, examined the association of radiological Boston CAA criteria and their constituent markers with hemorrhagic risks and functional outcomes after intravenous thrombolysis in the AcT trial (Alteplase Compared to Tenecteplase). METHODS: Blinded raters recorded lobar cerebral microbleeds, cortical superficial siderosis, white matter hyperintensity multispot sign, and centrum semiovale enlarged perivascular spaces, and classified possible and probable CAA according to radiological Boston criteria iterations, versions 1.0, 1.5, and 2.0. Multivariable logistic or ordinal regressions, adjusted for age, sex, baseline stroke severity, diabetes, hypertension, onset-to-needle time, thrombolytic agent, and endovascular therapy, assessed associations of these features/criteria with safety end points: symptomatic intracerebral hemorrhage (ICH), any ICH, Heidelberg hemorrhage grade, 90-day mortality, and functional outcomes (modified Rankin Scale score of 0-1 and ordinal modified Rankin Scale score shift). RESULTS: Among 1600 patients in the trial, 482 had suitable magnetic resonance imaging (mean age, 71 years; 47.1% female). Cortical superficial siderosis burden emerged as the dominant harmful marker: each increment was associated with increased risk of symptomatic ICH (adjusted odds ratio [aOR] per additional affected sulcus, 3.88 [95% CI, 2.87-5.26]), any ICH (aOR, 1.91 [95% CI, 1.22-2.98]), hemorrhage severity, 90-day mortality (aOR, 1.42 [95% CI, 1.18-1.71]), worse modified Rankin Scale scores (adjusted common odds ratio, 1.74 [95% CI, 1.58-1.91]), and lower odds of excellent functional recovery (aOR, 0.70 [95% CI, 0.64-0.77]). Fulfilling probable radiological Boston criteria, versions 1.0 and 1.5, increased odds of any ICH (aOR, 2.57 and 2.39 [95% CI, 2.05-3.23]; aOR, 2.39 [95% CI, 1.71-3.34], respectively), whereas fulfilling possible Boston criteria, version 1.5, was associated with worse modified Rankin Scale scores (adjusted common odds ratio, 2.34 [95% CI, 1.30-4.22]). Boston criteria, version 2.0, were not significantly associated with any hemorrhagic outcomes. CONCLUSIONS: In thrombolyzed patients with acute ischemic stroke, cortical superficial siderosis burden is strongly and consistently associated with higher risk of severe hemorrhage, disability, and death, making it a particularly relevant CAA marker when weighing thrombolytic risk versus benefit. Meeting radiological Boston criteria, versions 1.0 or 1.5, increases hemorrhagic risk, but meeting the latest 2.0 criteria does not.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.